主 办 单 位 各 有 关 单 位 各有关单位： 近年来，人工智能与合成生物学的快速发展给我国生物智造领域带来了巨大活力。其中，酶技术的 发展与应用是重要环节。 酶 具 有 加 速 或 减 慢 化 学 反 应 的 作 用 ， 因 其 反 应 特 点 可 发 展 许 多 应 用 场 景 ， 如 化 工 、 食 品 、 医 药、材料、医美、环境保护等多种领域。当前，科学家们已经可以通过人工智能设计新酶来实现新 场景应用，而 新酶的设计及酶技术的开发与应用对未来绿色催化领域的发展具有重要意义。所以 ，为了进一步提高从业者专业素质，促进酶技术的应用与发展，加快绿色经济生物智造进程，我单 位定于 2 0 2 5年5月2 3 - 2 5日 在 杭州 举 办 " 第 四 期 新 酶 设 计 及 酶 技 术 应 用 专 题 培 训 班 " 届 时将 邀 请行业内知名专家针对 相 关内 容 进 行 讲 解 与 探讨 。 参 会 名 额 有 限 ， 望 各 有 关 单 位 积 极 转 发 或 组织相关人员 尽快报名 参加。现将有关事项通知如下： 会 议 安 排 会议地点 ： 杭州（具体地点直接通知报名单位） 5月2 3日：全天报 ...

【SynBioCon】 获 悉， 4月29日，中国985高校中首个合成生物学学院—— 天津大学合成生物与生物制造学院揭牌成立 ，以主动应对新型人才培养、 生物技术革命和生物制造产业变革挑战，服务国家重大战略。 新成立的合成生物与生物制造学院将整合多学科资源，用人工智能赋能教学科研，搭建全方位的人才培养与科研创新平台。 据悉， 这是我国"世界一流 建设高校"中首个合成生物学院 ，也是天津大学统筹推进教育科技人才体制机制一体改革的重要举措。学院将以建设世界一流学科为目标，不断提升教学 科研水平，助力我国在合成生物学与生物制造领域不断取得新突破，为解决国家重大战略问题和全球性问题提供创新方案，培养创新人才。 据介绍，合成生物与生物制造致力于设计、改造乃至从头构建生物体系，以应对材料、能源、环境和健康等全球性挑战。据麦肯锡预测，未来全 球60%的物质可通过生物合成生产，潜在经济价值达30万亿美元。"合成生物"被列入我国《"十四五"规划和2035年远景目标纲要》，是具有 战略性、引领性和颠覆性的未来产业。 在合成生物学科研领域，天津大学实力雄厚，拥有合成生物技术全国重点实验室、教育部"珠峰计划"合成生物学前沿科学中心， ...

融行业智慧、共襄盛举 聚产业力量、擘画未来 作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

Core Viewpoint - The company, Qing Song Co., Ltd., is primarily engaged in the design, research and development, and manufacturing of cosmetics, including facial masks, skincare products, and wet wipes, with a significant focus on ODM (Original Design Manufacturer) services [6][8]. Company Overview - The company operates in the chemical raw materials and chemical products manufacturing industry, specifically in the cosmetics manufacturing sector [6]. - The main business entity is its wholly-owned subsidiary, Nuo Si Bei Cosmetics Co., Ltd., which contributes 99.52% of the consolidated revenue [8]. Business Operations - Nuo Si Bei specializes in the design, research and development, and manufacturing of facial masks, skincare products, wet wipes, and non-woven fabric products, making it one of the largest domestic ODM companies in China [8]. - The upstream supply chain includes natural cellulose fibers, polyester fibers, and viscose fibers for mask substrates, while the downstream market consists of cosmetic brand owners and various retail channels, including e-commerce and physical stores [9]. Financial Data - The company has not restated or adjusted previous years' financial data, indicating stability in its financial reporting [10]. - The company has implemented a share repurchase plan, with a total repurchase amount of approximately RMB 65.8 million, representing 3.49% of the total share capital [11]. Major Projects - The company has decided to terminate the construction of a large industrial park project on 148 acres and is negotiating with government authorities to return the land use rights [12][13]. - A new investment partnership has been formed with Mi Jia Technology Co., Ltd. to develop the 148-acre land project, with Nuo Si Bei holding a 20% stake in the newly established joint venture [13][14]. Strategic Investments - The company has increased its stake in Guangdong Ke Pu Rui Biotechnology Co., Ltd. to 60%, enhancing its capabilities in synthetic biology and new material technology [15]. - A new wholly-owned subsidiary, Guangdong Nuo Mi Jia Biomedical Co., Ltd., has been established to support the company's strategic development needs [16].

/D T 生物制造产业 交流 群/ 让专业的人聚在一起：绿色化工/生物基/食品和农业/美丽健康等10000+产业同行❤↓ DT合成生物制造交流群 陈经理 扫码添加微信,备注"单位、职务、姓名",进入群聊 Tel: 153-8139-7601 (微信同号) 生物制造产业社群专属 近日， 【SynBioCon】 获 悉， 4 月 21 日，由中国科学院天津工业生物技术研究所牵头承担的 国家重点研发计划 "合成生物学"重点专项 ——" 二氧化碳人工从头合成蛋白质"项目 启动会在中国 科学院天津工业生物技术研究所举行。 该项目对于推进我国绿色低碳发展、实现 "碳达峰、碳中和"与"粮食安全"的国家战略目标具有重大 意义。本次会议的召开， 标志着二氧化碳人工从头合成蛋白质研发工作全面启动。作为合成生物学 领域典型的学科交叉项目，其融合化学与生物技术，开创了二氧化碳和铵盐高效合成蛋白质的全新路 径 。项目通过解析碳氮固定原理、设计人工杂合系统，有望将蛋白质合成速率提升数十倍以上，为 蛋白质的工业化生产奠定基础，为全球碳资源利用和粮食可持续供应提供 "中国方案"。 从淀粉到蛋白，天工所的二氧化碳从头合成之路 早在2021年， ...

陈守文，湖北大学生命科学学院二级教授、博士生导师。省部共建生物催化与酶工程国家重点实验室PI，微生物细胞工厂湖北省工程研究中心主任，湖北省 环境微生物工程技术研究中心主任。国家百千万人才工程人选，国家有突出贡献中青年专家，国务院特殊津贴获得者，教育部新世纪人才，湖北省先进工作 者，楚天园丁奖。 主要从事地衣芽胞杆菌生物技术及合成生物学相关研究工作 ，先后主持国家重点研发计划、973计划、国家自然基金等国家级课题数10 余项，承担大型企业横向课题40余项，发表学术论文200余篇；出版著作10余部；授权中国发明专利80余件，美国发明专利2件，制定国家/行业标准3项， 获国家及省部级科技奖3项，其中，国家科学技术进步二等奖1项（序2）、湖北省技术发明一等奖2项（序1）。 近日， 【SynBioCon】 获 悉， 4月28日，庆祝中华全国总工会成立100周年暨全国劳动模范和先进工作者表彰大会 在人民大会堂举行，1670名全国 劳动模范756名全国先进工作者受到表彰。 湖北大学生命科学学院陈守文教授 荣获 "全国先进工作者" 称号并在京接受表彰。 针对聚谷氨酸发酵生产效率低、肥料应用技术缺乏等问题，他发明了 聚γ-谷氨 ...

Group 1: Financial Performance - The company's revenue for Q1 2025 reached 625.15 million CNY, representing a year-on-year growth of 20.35% [2] - The net profit attributable to shareholders for the same period was 51.12 million CNY, with a year-on-year increase of 13.23% [2] - The veterinary chemical drug revenue increased by 21.47% year-on-year, driven primarily by the sales of the product "Jinmei" [1] Group 2: Product Development and Market Strategy - The company plans to expand its product line with the new factory set to produce Jinmei, Tumei, and Qiangli products, enhancing its product diversity [1] - The R&D expenses grew by 27.03% in 2024, focusing on innovation and new product development [2] - The company has 16 vaccine products currently on the market and over 20 in the research and application phase [2] Group 3: Market Expansion and Competitive Advantage - The company exports 60-70% of its chemical products, with the U.S. being the primary market [5] - The introduction of the hydrochloride doxycycline project is expected to generate over 300 million CNY in revenue [3] - The company aims to enhance its market share in the veterinary vaccine sector by providing comprehensive technical solutions alongside its products [3] Group 4: Future Outlook and Industry Trends - The domestic veterinary drug market has a compound annual growth rate (CAGR) of 8.43% from 2019 to 2023, indicating significant growth potential [5] - The company anticipates that the market for veterinary biological products will expand, particularly with the ongoing development of the African swine fever vaccine [5] - The company is committed to strengthening its global presence and optimizing resource allocation to seize opportunities in the veterinary industry [6]

Core Viewpoint - The implementation of the new "National Nine Articles" has revitalized listed companies in the capital market, with Nanjing Hongtai Co., Ltd. being the first to complete a bankruptcy reorganization under this framework, showcasing market leadership [1] Financial Performance - In 2024, ST Hongtai reported a net asset increase of 196.02%, reaching 2.953 billion yuan, and reduced its asset-liability ratio from 89.89% at the beginning of the year to 59.35% by year-end, indicating a fundamental improvement in its financial structure [2] - The company achieved profitability in 2024, with a net profit attributable to shareholders of 388 million yuan [2] Business Strategy and Operations - ST Hongtai has a long-standing presence in the pesticide industry, holding over 50% of the global market share for key products such as pyridine and paraquat [3] - The company has successfully addressed historical debt issues and is focusing on strategic transformation and risk mitigation in 2024, emphasizing a dual approach of stabilizing development through reorganization and promoting growth through technological innovation [3] - The company has optimized its operational strategies in response to challenges in the pesticide industry, achieving price stabilization for core products and significant technological breakthroughs in its production processes [4] Expansion and Sustainability Initiatives - ST Hongtai is actively pursuing the "Belt and Road" initiative, establishing a base in Qujing, Yunnan, to leverage local resources and expand into Southeast Asian markets [5] - The company plans to develop several new projects, including a 50,000-ton pyridine cycle economy project and a 100,000-ton cassava bioethanol project, which will enhance its production capabilities and sustainability [5] Governance and Environmental Responsibility - In 2024, ST Hongtai made significant strides in corporate governance and environmental responsibility, receiving a standard unqualified audit report, which supports its application to remove risk warnings from its stock [6][7] - The company is committed to reducing pollution through the development of low-toxicity, high-efficiency products and is actively exploring green processes and circular economy models [7][8]

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

Core Insights - The article highlights the rapid growth of the ophthalmic drug market in China, with Kanghong Pharmaceutical's product "Langmu" breaking the monopoly of imported drugs and achieving significant sales [1][4][5] - Kanghong Pharmaceutical has established itself as a leader in the innovative drug sector, focusing on ophthalmology, mental health, and oncology, with a strong emphasis on innovation and quality [3][7][12] Company Performance - In 2024, Kanghong Pharmaceutical's biopharmaceutical business revenue reached 2.343 billion yuan, a year-on-year increase of 20.98%, accounting for 52.61% of total revenue [1] - The sales of Kanghong's product, Kangbaxip, reached 500 million yuan in 2023, capturing 36% of the market share [1] - The company has maintained a consistent growth trajectory for Kangbaxip over the past 11 years, with over 2.5 million injections administered [1][5] Market Dynamics - The global ophthalmic drug market is projected to reach $83.477 billion by 2031, with a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031 [3] - China has over 40 million patients with retinal diseases, with more than 3 million new patients added annually, indicating a significant market opportunity [4][8] Innovation and R&D - Kanghong Pharmaceutical has a comprehensive R&D strategy, with 21 marketed drugs, 10 of which are exclusive and 17 included in the national medical insurance directory [3][12] - The company is actively developing gene therapy and antibody drugs, with two ophthalmic products in clinical trials aimed at reducing injection frequency for patients [9][10] Production Capacity - Kanghong is investing in building production capabilities for gene therapy drugs, establishing a full-chain capability from R&D to commercialization [12][13] - The company has constructed GMP-compliant production bases in Beijing and Chengdu, enhancing its manufacturing capabilities for biopharmaceuticals [13]